Adlai Nortye Appoints Roger Sawhney, M.D. to Its Board of Directors
08 Aug 2024 //
GLOBENEWSWIRE
Adlai Nortye Encouraging Combo: An0025 Plus Dcrt At Asco 2024
23 May 2024 //
GLOBENEWSWIRE
Adlai Doses First Patient In AN0025 Rectal Cancer Trial
22 May 2024 //
GLOBENEWSWIRE
Adlai Nortye Announces Dr. Archie Tse as the Head of R&D
29 Mar 2024 //
GLOBENEWSWIRE
Adlai Nortye Announces Completion of Patient Enrollment in PIII of Buparlisib
17 Nov 2023 //
GLOBENEWSWIRE
Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award
23 Oct 2023 //
GLOBENEWSWIRE
Adlai Nortye Ltd. Announces Closing of Initial Public Offering
03 Oct 2023 //
GLOBENEWSWIRE
Adlai Nortye Ltd. Announces Pricing of Initial Public Offering
29 Sep 2023 //
GLOBENEWSWIRE
Adlai Nortye Advances Trial of Pelareorep-Paclitaxel Combo
24 Mar 2022 //
PRNEWSWIRE
Adlai Nortye Appoints Dr. Victoria Demby as SVP of Global Regulatory Affairs
14 Mar 2022 //
PRNEWSWIRE
Adlai Nortye Announces Publication of Preclinical Research of AN3025
21 Feb 2022 //
PRNEWSWIRE
Adlai Nortye, Biotime sign Licensing Agreement for Several Products
26 Jan 2022 //
PRNEWSWIRE
Adlai Nortye Begins Dosing in Trial Evaluating Pelareorep-Paclitaxel Combination
14 Oct 2021 //
PRNEWSWIRE
Adlai Nortye`s Patient Dosed in Phase Ia Clinical Trial of AN2025 and AN0025
07 Sep 2021 //
PRNEWSWIRE
China`s Adlai Nortye nabs another cool $100M for its immuno-oncology pipeline
15 Jul 2021 //
FIERCE BIOTECH
Adlai Nortye Announces First Patient Dosed in Global Ph III Trial of Buparlisib
15 Apr 2021 //
BIOSPACE
Adlai Nortye Announces First Patient Dosed in Global Ph III Trial of Buparlisib
15 Apr 2021 //
NEUROASIA
Chinese biopharma firm Adlai Nortye nets $100m in Series C round
31 Aug 2020 //
DEALSTREETASIA
Adlai Nortye Announces First Patient Dosed in Phase 1b Clinical Trial of AN0025
24 Aug 2020 //
PRNEWSWIRE
Adlai Nortye Announces First Patient Dosed in Phase 1b Clinical Trial of AN0025
24 Aug 2020 //
PRNEWSWIRE